Aurinia Pharmaceuticals Inc. has published a document presenting results from a Phase 1 study on Aritinercept (AUR200), a dual BAFF/APRIL inhibitor for potential treatment of autoimmune diseases. The document details the engineered features of Aritinercept and its ability to inhibit B cell proliferation mediated by BAFF and APRIL, compared to other dual BAFF/APRIL inhibitors. The full document can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.